(Q46714065)

24 December 2017

title

Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial (English)

1 reference

24 December 2017

primary biliary cholangitis

1 reference

0 references

author name string

Claudia O Zein

1

1 reference

24 December 2017

Roberta A Jorgensen

2

1 reference

24 December 2017

Bart Clarke

3

1 reference

24 December 2017

Doris E Wenger

4

1 reference

24 December 2017

Jill C Keach

5

1 reference

24 December 2017

Paul Angulo

6

1 reference

24 December 2017

Keith D Lindor

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

published in

Hepatology

1 reference

24 December 2017

volume

42

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

762-771

1 reference

24 December 2017

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

cites work

1 reference

Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

Bone disease and calcium absorption in primary biliary cirrhosis with special reference to vitamin-D therapy

21 January 2018

1 reference

7 January 2021

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.

1 reference

7 January 2021

Bone loss and reduced osteoblast function in primary biliary cirrhosis

1 reference

7 January 2021

Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease

1 reference

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

7 January 2021

Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment

1 reference

7 January 2021

Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years

1 reference

7 January 2021

Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial

1 reference

7 January 2021

Calcitriol for bone loss in patients with primary biliary cirrhosis.

1 reference

7 January 2021

Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis.

1 reference

7 January 2021

Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis

1 reference

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

7 January 2021

Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.

1 reference

7 January 2021

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

7 January 2021

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis

1 reference

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

7 January 2021

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

7 January 2021

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

1 reference

7 January 2021

Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study

1 reference

7 January 2021

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

7 January 2021

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

1 reference

7 January 2021

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

1 reference

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

7 January 2021

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

1 reference

7 January 2021

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

7 January 2021

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

7 January 2021

1 reference

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

7 January 2021

Alendronate-associated esophagitis: endoscopic and pathologic features

1 reference

7 January 2021

A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract

1 reference

7 January 2021

Effects of alendronate on gastric and duodenal mucosa

1 reference

7 January 2021

Alendronate gastric ulcers

1 reference

7 January 2021

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

7 January 2021

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

7 January 2021

Liver damage due to alendronate

1 reference

7 January 2021

Hepatitis after alendronate

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20866

1 reference

24 December 2017

PubMed ID

16175618

1 reference

24 December 2017